Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

1-s2.0-S0302283825005056-main.pdf (1.78 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-10-14
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227677

A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non–muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.eururo.2025.08.014

Resum

Intravesical bacillus Calmette-Gu & eacute;rin (BCG) is the standard treatment for high-risk non- muscle-invasive bladder cancer (NMIBC); however, recurrence and progression remain major challenges. To explore a heterologous prime-boost strategy, we conducted the RUTIVAC-1 trial (NCT03191578) to evaluate RUTI, a nonlive vaccine, derived from Mycobacterium tuberculosis, as a systemic primer prior to intravesical BCG in high-risk NMIBC patients. The immunogenicity, safety, and preliminary efficacy of RUTI was evaluated. In this phase 1, randomized, double-blind, placebo-controlled trial, 40 NMIBC patients were randomized 1:1 to receive two subcutaneous doses of RUTI (25 lg) or placebo before BCG treatment. Immunogenicity was assessed by flow cytometry, and clinical follow-up was extended to 5 yr. RUTI induced a systemic vaccine-specific response, increasing activation markers on CD4+ and CD8+ T cells, supporting effective immune priming. Regulatory T-cell expansion was observed in the placebo group but not in RUTI-vaccinated patients, who also exhibited amore heterogeneous and polyfunctional specific immune response. RUTI was safe and well tolerated, with only mild injectionsite reactions. Exploratory analyses showed a trend toward reduced recurrence, progression, and death, with improved 5-yr progression-free survival. The small sample size and baseline imbalances were the limitations. This phase 1 study supports the safety and immunogenicity of RUTI and provides encouraging data that warrant confirmation in larger t rials to establish its potential clinical benefit as a novel therapeutic strategy.

Matèries

Matèries (anglès)

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BUISAN, Oscar, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non–muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. European Urology. 2025. Vol. 89, num. 2, pags. 114-120. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/227677

Exportar metadades

JSON - METS

Compartir registre